Kelun-Biotech's Sac-TMT Lung Cancer Studies Highlighted at ESMO 2026

  • Kelun-Biotech's sacituzumab tirumotecan (sac-TMT) studies selected as Late-Breaking Abstracts (LBAs) at ESMO 2026.
  • Phase III studies OptiTROP-Lung04 and OptiTROP-Lung06 to be presented in the Lung Cancer Session on October 25.
  • Sac-TMT has four approved indications in China, with two new indication applications under priority review by NMPA.
  • MSD leading 18 global Phase III clinical studies of sac-TMT as monotherapy or in combination with pembrolizumab.

Kelun-Biotech's sac-TMT is positioning itself as a key player in the TROP2 ADC space, targeting advanced solid tumors. The focus on lung cancer and endometrial cancer studies at ESMO 2026 underscores the strategic importance of these indications. With MSD's global reach and Kelun-Biotech's proprietary technology, the collaboration aims to address unmet medical needs in both China and international markets.

Clinical Efficacy
Whether the Phase III study results for sac-TMT in lung cancer will demonstrate superior efficacy over existing treatments.
Regulatory Progress
The pace at which NMPA reviews and approves the two new indication applications for sac-TMT.
Global Expansion
How MSD's 18 ongoing global Phase III studies will impact sac-TMT's market potential outside Greater China.